Related Experiment Video
Updated: Mar 16, 2026
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Discovery and Evaluation of PRL Trimer Disruptors for Novel Anticancer Agents
Yunpeng Bai1, Zhi-Hong Yu1, Zhong-Yin Zhang2
1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN, 46202, USA.
Abstract:
Overexpression of PRL phosphatases (PRL1, PRL2, and PRL3) has been found in a variety of late-stage tumors and their distant metastatic sites. Therefore, the oncogenic PRL phosphatases represent intriguing targets for cancer therapy. There is considerable interest in identifying small molecule inhibitors targeting PRLs as novel anticancer agents. However, it has been difficult to acquire phosphatase activity-based PRL inhibitors due to the unusual wide and shallow catalytic pockets of PRLs revealed by crystal structure studies. Here, we present a novel method to identify PRL1 inhibitors by targeting the PRL1 trimer interface and the procedure to characterize their biochemical and cellular activity.
Insights
Novel strategies are needed to target oncogenic PRL phosphatases (PRL1, PRL2, and PRL3) in cancer therapy. This study presents a new method to identify PRL1 inhibitors by targeting its trimer interface, offering a promising approach for developing new anticancer drugs.
Area of Science:
- Biochemistry
- Oncology
- Drug Discovery
Background:
- Overexpression of PRL phosphatases (PRL1, PRL2, PRL3) is linked to advanced cancers and metastasis.
- PRL phosphatases are promising therapeutic targets for novel anticancer agents.
- Developing PRL inhibitors is challenging due to their unique catalytic pocket structures.
Purpose of the Study:
- To present a novel method for identifying PRL1 inhibitors.
- To target the PRL1 trimer interface for inhibitor development.
- To characterize the biochemical and cellular activity of identified PRL1 inhibitors.
Main Methods:
- Crystallographic studies to understand PRL structure.
- Development of a novel strategy targeting the PRL1 trimer interface.
- Biochemical assays to assess inhibitor activity.
- Cellular assays to evaluate efficacy in cancer models.
Main Results:
- A novel method for identifying PRL1 inhibitors was successfully developed.
- Inhibitors targeting the PRL1 trimer interface were identified.
- Biochemical and cellular characterization confirmed the activity of these inhibitors.
Conclusions:
- Targeting the PRL1 trimer interface is a viable strategy for developing novel PRL1 inhibitors.
- This approach offers a promising alternative to overcome challenges associated with traditional activity-based inhibition.
- The identified inhibitors represent potential new therapeutic agents for treating PRL-associated cancers.
